Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China
@article{ATM68995, author = {Xinglu Xu and Nan Fang and Huanan Li and Yanyan Liu and Fan Yang and Xin Li}, title = {Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China}, journal = {Annals of Translational Medicine}, volume = {9}, number = {9}, year = {2021}, keywords = {}, abstract = {}, issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/68995} }